On Jun. 20, 2025, CanSino Biologics announced that it had received the National Medical Products Administration’s (NMPA) permission for its PCV13i, a candidate 13-valent pneumococcal conjugate vaccine, by to start human clinical trials.

iPneucia^® is the first pneumococcal polysaccharide conjugate vaccine in China to adopt CRM197 and tetanus toxoid (TT) as carrier proteins, which improve immune response and effectively avoid adverse reactions due to excessive use of a single carrier.

Pneumonia is one of the most serious public health problem worldwide. According to the World Health Organization (WHO), this acute respiratory infectious diseases caused more than 1.6 million death cases every year, which become a leading cause of death among young children and the elderly globally¹. The disease, often cause by Streptococcus pneumonia, can lead to severe complications such as sepsis and meningitis if left untreated.

In China, approximately 550 thousand cases of pneumococcal pneumonia occur in children under 5 years old annually². Severe pneumococcal pneumonia accounts for 93% of all severe pneumonia cases³. One of the ideal strategies for developing new vaccines is to enhance the effectiveness against the serotypes with the heavy disease burden⁴.

iPneucia^® adopts a dual-carrier conjugate technology. This design not only reduce side effects from relying on single carrier, but also helps avoid interference when given with other vaccines⁵. Notably, the vaccine offers stronger protection against 4 key serotypes —— 19F, 19A, 7F, and 3 —— which cause the most serious pneumococcal infections among children in China^*.